No connection

Search Results

ABBV vs FOLD

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
FOLD
Amicus Therapeutics, Inc.
BEARISH
Price
$14.47
Market Cap
$4.54B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
FOLD
--
Forward P/E
ABBV
15.42
FOLD
17.67
P/B Ratio
ABBV
-146.66
FOLD
16.41
P/S Ratio
ABBV
6.5
FOLD
7.16
EV/EBITDA
ABBV
15.27
FOLD
111.86

Profitability

Gross Margin
ABBV
71.46%
FOLD
88.5%
Operating Margin
ABBV
35.5%
FOLD
8.61%
Profit Margin
ABBV
4.0%
FOLD
-4.28%
ROE
ABBV
137.96%
FOLD
-11.58%
ROA
ABBV
9.59%
FOLD
2.48%

Growth

Revenue Growth
ABBV
9.1%
FOLD
23.7%
Earnings Growth
ABBV
-88.7%
FOLD
-95.5%

Financial Health

Debt/Equity
ABBV
--
FOLD
1.61
Current Ratio
ABBV
0.72
FOLD
2.84
Quick Ratio
ABBV
0.47
FOLD
1.72

Dividends

Dividend Yield
ABBV
3.05%
FOLD
--
Payout Ratio
ABBV
490.15%
FOLD
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
FOLD BEARISH

FOLD exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While the company maintains impressive gross margins (88.5%) and revenue growth (23.7%), these are offset by a catastrophic collapse in earnings growth (-95.5% YoY) and negative ROE. The stock is currently trading at a 52-week high despite a bearish technical trend score (10/100) and aggressive insider selling by the CEO and other officers. The disconnect between the current price and the underlying deterministic health metrics suggests a high risk of a price correction.

Strengths
Exceptional gross margins of 88.50%
Strong year-over-year revenue growth of 23.70%
Robust short-term liquidity with a current ratio of 2.84
Risks
Critically low Piotroski F-Score (2/9) signaling financial instability
Severe earnings growth decline of -95.50% YoY
Heavy insider selling with 11 sell transactions and 0 buys

Compare Another Pair

ABBV vs FOLD: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Amicus Therapeutics, Inc. (FOLD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile